Ozanimod has similar target receptors (selective for S1P1 and S1P5) as siponimod and was recently approved by the FDA to treat relapsing forms of MS including active secondary progressive disease [266] based on results from phase 3 clinical trials (RADIANCE and SUNBEAM) [267, 268]. Here, S1PR1 is linked to myeloid sarcoma.